STRatifying Adult DIffuse Lower-grade Gliomas Based on Their VARIed Metabolic Profiles (STRADIVARI Project)
Launched by I.R.C.C.S OSPEDALE GALEAZZI-SANT'AMBROGIO · Jan 22, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The STRADIVARI Project is a clinical trial that aims to better understand lower-grade gliomas, which are a type of brain tumor. Researchers want to look more closely at these tumors' molecular and metabolic characteristics to identify different subgroups. These subgroups might behave differently and could respond to treatments in various ways. The study involves two groups: one group of participants will receive their usual treatment while their tumor samples will undergo advanced testing to see how their metabolic profiles relate to their treatment outcomes. The second group will include patients who have already had surgery, and their past medical records will be reviewed to see if certain biological markers can help predict their responses to treatment.
To participate in the trial, you need to have a brain tumor diagnosed as a lower-grade glioma and have a complete medical history. Unfortunately, if you are currently pregnant, breastfeeding, or unable to give informed consent, you won't be able to join. If you choose to participate, you'll receive routine care, and your tumor will be studied to help improve future treatments for this type of cancer. This study is important because it could lead to more personalized treatment options for people with lower-grade gliomas.
Gender
ALL
Eligibility criteria
- Prospective Metabolic Cohort:
- Inclusion Criteria:
- • Radiological diagnosis of brain tumor compatible with lower grade glioma
- • Full clinical history
- Exclusion Criteria:
- • Current pregnancy or lactation
- • Patients not able to provide informed consent
- Retrospective Cohort of FFPE samples:
- Inclusion Criteria:
- • Confirmed diagnosis of lower grade glioma
- • Full clinical and radiological history
About I.R.C.C.S Ospedale Galeazzi Sant'ambrogio
The I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio is a leading clinical research institute and hospital in Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As a designated Institute of Hospitalization and Care of Scientific Relevance (I.R.C.C.S.), it focuses on translational research that bridges the gap between laboratory findings and clinical applications. The facility is equipped with state-of-the-art technology and a multidisciplinary team of experts, enabling it to conduct a wide range of clinical trials aimed at improving treatment outcomes across various medical fields. Its dedication to ethical practices and patient safety ensures that all research activities align with the highest international standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bari, Puglia, Italy
Milano, Lombardy, Italy
Milano, Lombardy, Italy
Bari, Puglia, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported